Medtronic plc (MDTC34) Fair Value & Analysis
Healthcare · BR · Market cap R$541B
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 12 days ago
Share price +17.3% over the past month.
Price vs Fair Value (12 months)
12‑month range R$172.05 – R$255.99 · fair‑value band R$17.12 – R$43.66 · the R$203.91 price screens above the R$27.47 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medtronic plc (MDTC34) currently trades at R$203.91, while our model-based Fair Value estimate is R$27.47 — implying the stock looks roughly 86.5% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medtronic plc generated revenue of R$36.4B at a net margin of 13.2%. Revenue grew 9.9% year over year. It earns a return on equity of 9.9%. Net debt stands at R$26.2B. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$17.12 (bear case) to R$43.66 (bull case); at R$203.91, the current price sits above that range. The share trades about 26% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside — at -87%, MDTC34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medtronic plc reported revenue of R$33.5B in FY2025 versus R$30.1B in FY2021, a compound +2.7%/yr. Reported net income was R$4.7B in FY2025, compounding +6.6%/yr from FY2021.
Is MDTC34 fairly valued? → Check now
Recent news
- Why Is Medtronic (MDT) Up 1.5% Since Last Earnings Report?
- Medtronic (MDT) Alerts Cyberattack Victims While Expanding Retia Cardiac Monitoring Partnership
- Medtronic plc (MDT) & Retia Expand Partnership to Target High-Risk Surgical and Critically ill Patients
- Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$39.41 | R$30.42 | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
| STERIS plc STE | $200.40 | $176.96 | -12% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medtronic plc (MDTC34) undervalued?
What is the fair value of MDTC34?
What is the quality score of MDTC34?
What is the revenue of Medtronic plc (MDTC34)?
What is the net profit margin of MDTC34?
Does Medtronic plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.